Thomas White International Ltd. held its stake in shares of Allergan PLC. (NYSE:AGN) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,316 shares of the company’s stock at the close of the 2nd quarter. Thomas White International Ltd.’s holdings in Allergan PLC. were worth $1,049,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Veritas Asset Management LLP purchased a new stake in shares of Allergan PLC. in the 1st quarter valued at approximately $761,339,000. Edgewood Management LLC grew its stake in shares of Allergan PLC. by 7.0% in the 1st quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock valued at $646,090,000 after buying an additional 178,055 shares during the period. Epoch Investment Partners Inc. grew its stake in shares of Allergan PLC. by 3.8% in the 1st quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after buying an additional 73,081 shares during the period. UBS Asset Management Americas Inc. grew its stake in shares of Allergan PLC. by 0.3% in the 1st quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock valued at $476,713,000 after buying an additional 5,042 shares during the period. Finally, Blue Ridge Capital L.L.C. grew its stake in shares of Allergan PLC. by 24.1% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares during the period. 82.02% of the stock is owned by institutional investors.

Shares of Allergan PLC. (AGN) opened at 215.00 on Wednesday. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The firm has a market capitalization of $71.88 billion, a price-to-earnings ratio of 6.55 and a beta of 1.18. The firm’s 50-day moving average is $229.79 and its 200-day moving average is $236.07.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the firm earned $3.35 earnings per share. Allergan PLC.’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities research analysts forecast that Allergan PLC. will post $16.25 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were given a dividend of $0.70 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.30%. Allergan PLC.’s payout ratio is currently 9.95%.

AGN has been the subject of several analyst reports. Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price target for the company in a research note on Tuesday, July 11th. BidaskClub raised shares of Allergan PLC. from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Royal Bank Of Canada set a $284.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Monday, June 12th. Mizuho dropped their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research note on Friday, June 9th. Finally, Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Thursday, June 8th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $274.69.

WARNING: “Allergan PLC. (AGN) Holdings Held by Thomas White International Ltd.” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/20/allergan-plc-agn-holdings-held-by-thomas-white-international-ltd.html.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.